HUMAN PAPILLOMA VIRUS- RELATED DISEASE AND HPV VACCINATION

The recently approved quadrivalent Human papilloma virus vaccine targets the Human papilloma virus (HPV) strains responsible for approximately 70% of cervical cancers and 90% of genital warts. It is also effective in reducing the incidence of HPV-related conditions, especially when given prior to exposure to HPV. The vaccine is recommended for all girls aged 11 to 12 years followed by 2nd vaccination for women up to the age of 26. Most insurance plans cover the vaccine. Human papilloma virus is the most common sexually transmitted infection in the United States and persistent HPV infection is strongly associated with risk of cervical cancer and genital warts. HPV vaccination reduces the incidence of HPV-related cancers and precancerous lesions in the United States and abroad, though decisions regarding implementation of vaccination remain.